- Home
- MRNA vs BIIB Comparison
MRNA vs BIIB Comparison
Compare MRNA & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRNA | BIIB |
|---|---|---|
| Founded | 2010 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.7B | 29.9B |
| IPO Year | 2018 | 1996 |
Fundamental Metrics
Financial Performance| Metric | MRNA | BIIB |
|---|---|---|
| Price | $54.50 | $202.95 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 12 | 25 |
| Target Price | $34.27 | ★ $206.83 |
| AVG Volume (30 Days) | ★ 6.0M | 1.4M |
| Earning Date | 05-01-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.77 | N/A |
| EPS | N/A | ★ 2.15 |
| Revenue | ★ $19,263,000,000.00 | $9,890,600,000.00 |
| Revenue This Year | $9.36 | N/A |
| Revenue Next Year | $15.43 | N/A |
| P/E Ratio | ★ N/A | $96.33 |
| Revenue Growth | ★ 4.29 | 2.22 |
| 52 Week Low | $22.28 | $127.00 |
| 52 Week High | $85.60 | $219.72 |
Technical Indicators
Market Signals| Indicator | MRNA | BIIB |
|---|---|---|
| Relative Strength Index (RSI) | 43.15 | 51.86 |
| Support Level | $45.09 | $186.24 |
| Resistance Level | $59.52 | $217.76 |
| Average True Range (ATR) | 2.79 | 8.46 |
| MACD | -1.28 | 0.28 |
| Stochastic Oscillator | 20.90 | 58.24 |
Price Performance
Historical ComparisonAbout MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
About BIIB Biogen Inc.
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).